Journals / MN Oftalmoloji / 2018 / Cilt: 25 - Sayı: 3

Intravitreal Dexamethasone Implant and Ranibizumab in the Treatment of Retinal Vein Occlusion: Six-month Results

Retinal Ven Tıkanıklığı Tedavisinde İntravitreal Deksametazon İmplant ile Ranibizumab: Altı Aylık Sonuçlar

Pages
152–159
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: According to the results of our study, both dexamethasone implantation and ranibizumab injections were effective in treating macular edema.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The objectives were to evaluate visual acuity, macular thickness and intraocular pressure after intravitreal ranibizumab or dex- amethasone injection for macular edema due to retinal vein occlusion.
📊
Key Findings & Data:Material and Method: We retrospectively studied 61 eyes of 61 patients with macular edema secondary to retinal vein occlusion, who were treated with intravitreal dexamethasone or ranibizumab.
💡
Conclusion & Impact:Conclusion: According to the results of our study, both dexamethasone implantation and ranibizumab injections were effective in treating macular edema.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The objectives were to evaluate visual acuity, macular thickness and intraocular pressure after intravitreal ranibizumab or dex- amethasone injection for macular edema due to retinal vein occlusion. Material and Method: We retrospectively studied 61 eyes of 61 patients with macular edema secondary to retinal vein occlusion, who were treated with intravitreal dexamethasone or ranibizumab. Since the duration of the Dexamethasone implant was assessed as 6 months, patients treated with single dose dexamethasone were studied. Ranibizumab injections were included in the study of patients who were given doses in the first 3 months as dosing doses. Each patient had ophthalmological examination including best corrected visual acuity, central macular thickness and intraocular pressure measurement before and after the injections. One month, 3 month and 6 month visit was recorded. Retinal vein occlusion complications and change in visual acuity, central macular thickness and intraocular pressure were recorded. Results: Repeated intravitreal ranibizumab injections and intravitreal dexamethasone implantation in retinal vein occlusion patients re- sulted in a statistically significant improvement in visual acuity and macular edema at each follow-up. The intraocular pressure should be closely followed after dexamethasone implantation. Conclusion: According to the results of our study, both dexamethasone implantation and ranibizumab injections were effective in treating macular edema. There was no significant difference between the groups. However, the newly developed intraocular pressure rate in the dex- amethasone group is significantly higher at 1 month than the other group. Therefore, ranibizumab treatment seems to be a safer method in terms of ocular hypertension development than dexamethasone treatment, which has the same efficacy.

Özet

Amaç: Retina ven tıkanıklığına bağlı maküla ödemi tedavisinde intravitreal deksametazon veya ranibizumab enjeksiyonu sonrası maküla kalınlığı, görme keskinliği ve göz içi basıncı değişikliklerinin belirlenmesi. Gereç ve Yöntem: Bu retrospektif çalışmada retina ven tıkanıklığına bağlı maküla ödemi tedavisi için intravitreal deksametazon veya ra- nibizumab enjeksiyonu uygulanan 61 hastanın 61 gözü incelendi. Deksametazon implantın etki süresi 6 ay olarak değerlendirildiği için tek doz deksametazon olarak uygulanan hastalar incelendi. Ranibizumab enjeksiyonları ise ilk 3 ay birer doz olacak şekilde yükleme dozu yapılan has- talar çalışmaya dahil edildi. Hastaların enjeksiyon öncesi, enjeksiyon sonrası 1. ay, 3. ay ve 6. ay en iyi düzeltilmiş görme keskinliği, maküla kalınlığı ve göz içi basıncı değişiklikleri, demografik verileri ve komplikasyonlar değerlendirildi. Bulgular: Retina ven tıkanıklığı olgularının intravitreal deksametazon ve ranibizumab uygulaması öncesi ortalama en iyi düzeltilmiş gör- me keskinliği ve ortalama maküla kalınlıkları ile 1.ay, 3.ay, 6.ay ortalama en iyi düzeltilmiş görme keskinliği arasında istatistiksel anlamlı ar- tış, ortalama maküla kalınlığında anlamlı azalma tespit edildi. (p 0,05). Sonuç: Retina ven tıkanıklığı hastalarında tekrarlanan intravitreal ranibizumab enjeksiyonları ve intravitreal deksametazon implantı ile görme keskinliğinde ve maküla ödeminde istatistiksel olarak anlamlı düzelme görülmüştür. İki grup arasında anlamlı bir farklılık saptanmadı. Bununla birlikte, göz içi basınç artışı oranının deksametazon grubunda 1. ayda diğer gruba göre anlamlı derecede yüksek olduğu görülmekte- dir. Bu nedenle, ranibizumab tedavisi, aynı etkiye sahip olan deksametazon tedavisine göre oküler hipertansiyon gelişiminde daha güvenli bir yöntem gibi gözükmektedir.

🔖

Cite This Article

BİKE, H. İ., SEVER, Ö., HOROZOĞLU, F. (2018). Intravitreal Dexamethasone Implant and Ranibizumab in the Treatment of Retinal Vein Occlusion: Six-month Results. MN Oftalmoloji, Cilt: 25 - Sayı: 3, 152–159. https://ajindex.com/articles/295511

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Branch Vein Occlusion Study Group. Argon Laser Photoco agula - tion for Macular Edema in Branch Vein Occlusion. Am J Ophtalmol 1984;98:271-82.
  2. Klein R, Klein BE, Moss SE, Meuer SM.The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study.Trans Am Ophthalmol Soc. 2000;98:133-41
  3. Campochiero PA, Hafiz G, Shah SM, et al. Ranibizumab for mac- ular edema due to retinal vein occlusions: implication VEGF as a critical stimulator. Mol Ther 2008;16(4):791-9.
  4. Özmen MC, Özdek Ş. Retina ven tıkanıklıklarına bağlı gelişen maküla ödeminde güncel tedavi yöntemleri. Retina-Vitreus 2008;16(1):1-8 Saatci Ali O. Laser applications formacular edema due to retinal vein occlusions. T Klin J Ophthalmol-Special Topics 2013; 6(1): 136-9
  5. Ferris FL III, Patz A. Macular Edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984;28:452-61.
  6. Joshi L, Yaganti S, Gemenetzi M, et al. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using re- peat injections as-needed. Br J Ophthalmol. 2013 Aug;97(8): 1040-4.
  7. Querques G, Cascavilla ML, Cavallero E, et al. Changes in mac- ular function after ozurdex for retinal vein occlusion. Optom Vis Sci 2014 Jul;91(7):760-8.
  8. Adamis AP, Miller JW, Bernal MT, et al. Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy. Am J Ophthalmol 1994;118: 445-50.
  9. Boyd SR, Zachary I, Chakravarthy U, et al.: Correlation of in- creased vascular endothelial growth factor with neovasculariza- tion and permeability in ischemic central vein occlusion. Arch Ophthalmol.2002;120:1644-50.
  10. Noma H, Funatsu H, Mimura T, Tatsugawa M,Shimada K, Eguchi S. Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion. Retina 2012;32(1):86-91.
  11. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein oc- clusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117(6):1102-12.
  12. Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion:six-month primary end point results of a phase III study. Ophthalmology 2010;117(6):1124-33.
  13. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in pa- tients wit